Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
48,652,936
-
Share change
-
-663,664
-
Total reported value
-
$2,168,519,107
-
Put/Call ratio
-
37%
-
Price per share
-
$44.57
-
Number of holders
-
160
-
Value change
-
-$3,347,309
-
Number of buys
-
76
-
Number of sells
-
72
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2022
As of 31 Dec 2022,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,652,936 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., RTW INVESTMENTS, LP, VANGUARD GROUP INC, STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., Redmile Group, LLC, Bellevue Group AG, and Kynam Capital Management, LP.
This page lists
162
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.